Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Lorenzi

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Nature Communications|April 18, 2019
Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patientsXu-Chao Zhang, Jun Wang, Guo-Guang Shao, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitorsKurt Zimmermann, Xiaopeng Sang, Harold A Mastalerz, et al.
JTO Clinical and Research Reports|September 30, 2021
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted <i>Listeria monocytogenes</i>-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 StudiesJulie R Brahmer, Melissa L Johnson, Manuel Cobo, et al.
Cancer Research|May 25, 2016
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung TumorsSheri L Moores, Mark L Chiu, Barbara S Bushey, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Cancer Discovery|May 17, 2020
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-Driven NSCLCJiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, et al.
Genetics|March 4, 2005
Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase geneKyle A Edgar, Marcia Belvin, Annette L Parks, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Cancer Immunology Research|July 24, 2019
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor ImmunitySangeetha Palakurthi, Mari Kuraguchi, Sima J Zacharek, et al.
Molecular Cancer Therapeutics|March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family InhibitorTimothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Nature Communications|April 18, 2019
Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patientsXu-Chao Zhang, Jun Wang, Guo-Guang Shao, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitorsKurt Zimmermann, Xiaopeng Sang, Harold A Mastalerz, et al.
JTO Clinical and Research Reports|September 30, 2021
JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted <i>Listeria monocytogenes</i>-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 StudiesJulie R Brahmer, Melissa L Johnson, Manuel Cobo, et al.
Cancer Research|May 25, 2016
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung TumorsSheri L Moores, Mark L Chiu, Barbara S Bushey, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Cancer Discovery|May 17, 2020
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion-Driven NSCLCJiyeon Yun, Soo-Hwan Lee, Seok-Young Kim, et al.
Genetics|March 4, 2005
Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase geneKyle A Edgar, Marcia Belvin, Annette L Parks, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Cancer Immunology Research|July 24, 2019
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor ImmunitySangeetha Palakurthi, Mari Kuraguchi, Sima J Zacharek, et al.
Molecular Cancer Therapeutics|March 26, 2017
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family InhibitorTimothy P S Perera, Eleonora Jovcheva, Laurence Mevellec, et al.
Pageof 7